2024. Continuous Tralokinumab Treatment over 4 Years in Adults with Moderate-to-Severe Atopic Dermatitis Provides Long-Term Disease Control. SKIN The Journal of Cutaneous Medicine. 8, 2 (Mar. 2024), s376. DOI:https://doi.org/10.25251/skin.8.supp.376.